After achieving sustained clinical remission, treatment was stopped and participants were followed in routine clinical practice to evaluate the possibility of maintaining drug-free remission. In univariate analysis, only sex and baseline BASDAI score were significantly different between those who did and did not achieve sustained clinical remission. Of those who achieved sustained clinical remission and were taken off treatment, 84.8 per cent experienced a disease relapse within one year. However, inducing drug-free remission in axSpA remains challenging. Treat-to-target approach allows to induce sustained clinical remission in over 60 per cent of patients with early axial spondyloarthritis.

Source: Irish Independent July 22, 2024 20:06 UTC